R & D Pharma
R&D Pharma is a privately held Monaco-based pharmaceutical laboratory founded in 2001 that operates as a Marketing Authorization Holder in France, marketing two authorized herbal medicinal products (Dolosoft and Prosoft) while developing investigational dermatology medical devices for age-related skin conditions.
- Company typePrivate
- Founded2001
- HeadquartersMonaco, Monaco
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What R & D Pharma does
R&D Pharma is a privately held, independent pharmaceutical laboratory founded in 2001 and headquartered in the Principality of Monaco (Le Triton, 5 Rue du Gabian). The company operates in a dual regulatory capacity: as a Marketing Authorization Holder (MAH) with exploitant status under French pharmaceutical law distributing authorized medicinal products in France, and as a Manufacturer and Distributor under the EU Medical Device Regulation (EU 2017/745) with ISO 13485 Quality Management System certification. Its commercial portfolio currently consists of two authorized herbal medicinal products—Dolosoft (a traditional herbal product containing Harpagophytum dry extract for musculoskeletal conditions) and Prosoft (a well-established use herbal product for mental well-being)—both holding valid national Marketing Authorizations in France and distributed through authorized pharmaceutical wholesale channels. Pricing follows the regulatory-approved framework in France and is not publicly disclosed.
Beyond its marketed pharmaceutical business, R&D Pharma is advancing a pipeline of investigational dermatology medical devices. MDC-75 is a Class IIa device currently under regulatory review for benign superficial skin lesions including actinic keratosis, and MDC-85 is an investigational device in clinical investigation phase for superficial basal cell carcinoma (sBCC); neither is CE marked nor commercially available in the European Union. Pharmaceutical manufacturing is outsourced to GMP-compliant Contract Development and Manufacturing Organization (CDMO) partners, while R&D Pharma retains batch certification and release responsibility. The company maintains Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) compliance for its clinical investigations, pharmacovigilance and post-market surveillance infrastructure, and an Investigator-Initiated Research (IIR) program for external scientific collaboration.
The go-to-market model is B2B and regulatory-driven: products reach end-users via authorized French wholesale distribution, with a recently launched WooCommerce-based direct-to-consumer e-commerce storefront currently listing placeholder test products. End customers are patients with age-related dermatological, musculoskeletal, and mental well-being conditions. The organization is described as a "human-sized" agile team with multidisciplinary expertise spanning clinical research, regulatory affairs, quality management, pharmaceutical affairs, and medical device development. Revenue, headcount, and ownership structure are not publicly disclosed; the company appears to be founder-owned or closely held with no parent, no external investors documented, and no public listing.
R & D Pharma firmographics
Firmographics- Name
- R & D Pharma
- Legal name
- R&D Pharma
- Website
- https://rd-pharma.mc
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- R&D Pharma is a privately held Monaco-based pharmaceutical laboratory founded in 2001 that operates as a Marketing Authorization Holder in France, marketing two authorized herbal medicinal products (Dolosoft and Prosoft) while developing investigational dermatology medical devices for age-related skin conditions.
- Ownership category
- akta.pro rank
R & D Pharma industry classification
Industry- Product category
- Specialty Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermatology Specialty Pharmaceuticals (HLAIACAL)
Keywords
Where R & D Pharma is headquartered
LocationHeadquarters
- HQ city
- Monaco
- HQ country
- Monaco
- HQ region
- Europe
Offices1 record
Markets served
R & D Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Sales of market-authorized medicinal products including Dolosoft (herbal product for musculoskeletal conditions) and Prosoft (herbal product for mental well-being). Products hold valid national Marketing Authorization in France.
- Medical Device Development: Development of investigational dermatology medical devices (MDC-75, MDC-85) currently under regulatory review or clinical investigation. Not yet commercially available.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | One time/ perpetual license | E-commerce test products |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels2 records
R & D Pharma product offering
Product offeringCore offering
R&D Pharma operates as a Marketing Authorization Holder (MAH) and developer of pharmaceutical products and dermatology medical devices. Its marketed portfolio consists of two herbal medicinal products authorized in France—Dolosoft (Harpagophytum extract for musculoskeletal conditions) and Prosoft (herbal product for mental well-being). The company is also developing investigational Class IIa dermatology medical devices (MDC-75 for skin lesions including actinic keratosis, MDC-85 for superficial basal cell carcinoma) currently in regulatory review or clinical investigation. Manufacturing is outsourced to qualified GMP-compliant CDMO partners.
Product overview
R&D Pharma operates as a Marketing Authorization Holder with two authorized pharmaceutical products—Dolosoft (herbal medicinal product for musculoskeletal conditions) and Prosoft (herbal medicinal product for mental well-being)—both holding valid national Marketing Authorizations in France. In addition to its pharmaceutical portfolio, R&D Pharma is developing investigational dermatological medical devices, including MDC-75 (Class IIa device under regulatory review for skin lesions including actinic keratosis) and MDC-85 (device in clinical investigation for superficial basal cell carcinoma). The investigational devices are not yet CE marked or commercially available.
Differentiator
Problem solved
Functional benefit
Brands
- Dolosoft: Registered traditional herbal medicinal product containing a dry extract of Harpagophytum, traditionally used in musculoskeletal conditions. Holds valid national Marketing Authorization in France.
- Prosoft
- MDC-75
- MDC-85
Products and services
- Dolosoft
- Prosoft
- MDC-75
- MDC-85
Companies that use R & D Pharma
Customer profileSegments3 records
Ideal customer profiles3 records
R & D Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
R & D Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GMP-compliant CDMO partnerscoreR&D Pharma outsources pharmaceutical manufacturing to qualified GMP-compliant Contract Development and Manufacturing Organization (CDMO) partners. The company holds appropriate GMP authorization related to batch certification and release, enabling strengthened quality control and close collaboration with manufacturing partners.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
R & D Pharma competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
R & D Pharma social profiles
Digital presenceR & D Pharma compliance and trust
Trust signalCompliance4 records
R & D Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
R & D Pharma leadership team
Management profileNumber of profiles
R & D Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
R & D Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about R & D Pharma
What does R & D Pharma do?
R&D Pharma operates as a Marketing Authorization Holder (MAH) and developer of pharmaceutical products and dermatology medical devices. Its marketed portfolio consists of two herbal medicinal products authorized in France—Dolosoft (Harpagophytum extract for musculoskeletal conditions) and Prosoft (herbal product for mental well-being). The company is also developing investigational Class IIa dermatology medical devices (MDC-75 for skin lesions including actinic keratosis, MDC-85 for superficial basal cell carcinoma) currently in regulatory review or clinical investigation. Manufacturing is outsourced to qualified GMP-compliant CDMO partners.
Is R & D Pharma a public or private company?
R & D Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was R & D Pharma founded?
R & D Pharma was founded in 2001. It employs 11 to 50 people.
Where is R & D Pharma based?
R & D Pharma is headquartered in Monaco, Monaco, in the Europe region.
How does R & D Pharma make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are medical Device Development.
Does R & D Pharma have an API?
No public API is recorded for R & D Pharma.
What industry is R & D Pharma in?
R & D Pharma's product category is Specialty Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.